Business
Sotera Health Reports Fourth-Quarter and Full-Year 2020 Results; Provides 2021 Outlook
Q4 2020 net revenues of $217 million increased 12%, compared to Q4 2019Q4 2020 net loss of $44 million or $0.17 per diluted share, compared to a net loss of
About this update from Sotera Health Company
[{"type":"text","content":"Q4 2020 net revenues of $217 million increased 12%, compared to Q4 2019Q4 2020 net loss of $44 million or $0.17 per diluted share, compared to a net loss of $28 million or $0.12 per diluted share in Q4 2019; Q4 2020 and Q4 2019 include losses on extinguishment of debt of $44 million and $30 million, respectivelyQ4 2020 Adjusted EBITDA of $113 million increased 20%, compared to Q4 2019Q4 2020 Adjusted EPS of $0.09 improved by $0.04 per diluted share, compared to Q4 2019December 31, 2020 total debt of $1,861 million, net debt of $1,797 million, and net leverage ratio reduced to 4.3xFull-year 2021 outlook revenue growth of 9% to 12% CLEVELAND, March 09, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2020. Fourth-quarter 2020 net revenues increased 12% to $217 million, compared with $193 million in the fourth-quarter a year ago. Net loss attributable to Sotera Health (“net loss”) was $44 million, or $0.17 per diluted share, compared with a net loss of $28 million, or $0.12 per diluted share in the fourth-quarter 2019. Fourth-quarter 2020 net loss included a $44 million charge related to the previously announced paydown of $1,111 million of debt with proceeds from the Company’s initial public offering, and fourth-quarter 2019 net loss included a $30 million charge related to the refinancing of debt. Adjusted EBITDA for the fourth-quarter 2020 increased by 20% to $113 million over the prior-year quarter. Fourth-quarter 2020 Adjusted earnings per diluted share (“Adjusted EPS”) was $0.09, an increase of $0.04 per diluted share, compared to the fourth-quarter 2019. Please refer to the section “Non-GAAP Financial Measures” provided later in this release. For full-year 2020, net revenues increased 5% to $818 million, compared with $778 million for 2019. Full-year 2020 net loss was $39 million, or $0.16 per diluted share, compared with a net loss of $21 million, or $0.09 per diluted share, for 2019. Full-year 2020 and 2019 net losses included the $44 million and $30 million charges referenced above. Full-year 2020 Adjusted EBITDA increased nearly 11% to $420 million, compared to 2019. Adjusted EPS was $0.42 in 202...